Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Crinetics Pharmaceuticals (NAS:CRNX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Crinetics Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

6Z4:Germany

Address

10222 Barnes Canyon Road, Building No. 2, San Diego, CA, USA, 92121

Website

https://www.crinetics.com

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Executives

Stephen F. Betz	officer: Chief Scientific Officer	10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson	officer: See Remarks	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard Scott Struthers	director, officer: See Remarks	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Alan Seth Krasner	officer: Chief Medical Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio	director	225 SECOND AVENUE, WALTHAM MA 02451
Jeff E. Knight	officer: Chief Operating Officer	CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf	director	C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Ajay Madan	officer: Chief Development Officer	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003